Evolva Holding SA (ELVAF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2.58 Million CHF | 169.21% |
| 2022 | -6 Million CHF | 35.46% |
| 2021 | -9.3 Million CHF | -315.13% |
| 2020 | -2.24 Million CHF | -142.36% |
| 2019 | 5.29 Million CHF | 200.02% |
| 2018 | -5.29 Million CHF | 12.93% |
| 2017 | -6.07 Million CHF | -345.51% |
| 2016 | -1.36 Million CHF | -259.25% |
| 2015 | 856.4 Thousand CHF | 106.39% |
| 2014 | -13.4 Million CHF | -31.81% |
| 2013 | -10.16 Million CHF | 18.28% |
| 2012 | -12.44 Million CHF | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q2 | -3.24 Million CHF | -564.36% |
| 2023 Q4 | -2.86 Million CHF | 0.0% |
| 2023 Q3 | -2.86 Million CHF | 11.89% |
| 2023 FY | 4.15 Million CHF | 169.21% |
| 2023 Q1 | -489.15 Thousand CHF | 83.78% |
| 2022 FY | -6 Million CHF | 35.46% |
| 2022 Q3 | -244.65 Thousand CHF | 95.84% |
| 2022 Q4 | -3.01 Million CHF | -1132.54% |
| 2022 Q2 | -5.87 Million CHF | -1008.95% |
| 2022 Q1 | -529.95 Thousand CHF | 91.39% |
| 2021 Q1 | -3.15 Million CHF | 44.18% |
| 2021 Q2 | -9.91 Million CHF | -214.6% |
| 2021 FY | -9.3 Million CHF | -315.13% |
| 2021 Q3 | -1.5 Million CHF | 84.86% |
| 2021 Q4 | -6.15 Million CHF | -310.16% |
| 2020 Q2 | -4.26 Million CHF | -4504.21% |
| 2020 Q4 | -5.64 Million CHF | -449.1% |
| 2020 Q1 | -92.7 Thousand CHF | 94.52% |
| 2020 Q3 | -1.02 Million CHF | 75.91% |
| 2020 FY | -2.24 Million CHF | -142.36% |
| 2019 Q4 | -1.69 Million CHF | -266.34% |
| 2019 Q3 | 1.01 Million CHF | 232.53% |
| 2019 Q2 | -767.8 Thousand CHF | -147.16% |
| 2019 Q1 | 1.62 Million CHF | 181.88% |
| 2019 FY | 5.29 Million CHF | 200.02% |
| 2018 Q2 | 480.85 Thousand CHF | 0.0% |
| 2018 Q3 | 577.6 Thousand CHF | 20.12% |
| 2018 FY | -5.29 Million CHF | 12.93% |
| 2018 Q4 | 577.6 Thousand CHF | 0.0% |
| 2018 Q1 | 480.85 Thousand CHF | 112.93% |
| 2017 Q3 | -3.71 Million CHF | 36.68% |
| 2017 Q4 | -3.71 Million CHF | 0.0% |
| 2017 FY | -6.07 Million CHF | -345.51% |
| 2017 Q2 | -5.87 Million CHF | 0.0% |
| 2017 Q1 | -5.87 Million CHF | 9.54% |
| 2016 Q3 | -6.49 Million CHF | 3.19% |
| 2016 FY | -1.36 Million CHF | -259.25% |
| 2016 Q1 | -6.7 Million CHF | -6.76% |
| 2016 Q2 | -6.7 Million CHF | 0.0% |
| 2016 Q4 | -6.49 Million CHF | 0.0% |
| 2015 Q1 | -5.34 Million CHF | -56.22% |
| 2015 Q4 | -6.28 Million CHF | 0.0% |
| 2015 Q3 | -6.28 Million CHF | -17.46% |
| 2015 FY | 856.4 Thousand CHF | 106.39% |
| 2015 Q2 | -5.34 Million CHF | 0.0% |
| 2014 FY | -13.4 Million CHF | -31.81% |
| 2014 Q3 | -3.42 Million CHF | -4.43% |
| 2014 Q1 | -3.27 Million CHF | -43.08% |
| 2014 Q2 | -3.27 Million CHF | 0.0% |
| 2014 Q4 | -3.42 Million CHF | 0.0% |
| 2013 Q4 | -2.29 Million CHF | 0.0% |
| 2013 FY | -10.16 Million CHF | 18.28% |
| 2013 Q1 | -2.79 Million CHF | 7.08% |
| 2013 Q2 | -2.79 Million CHF | 0.0% |
| 2013 Q3 | -2.29 Million CHF | 17.97% |
| 2012 Q4 | -3 Million CHF | 0.0% |
| 2012 Q3 | -3 Million CHF | 0.0% |
| 2012 FY | -12.44 Million CHF | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 117.218% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 83355.964% |
| SQZ Biotechnologies Company | 9.79 Million USD | 126.369% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 122.062% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 102.168% |
| Mesoblast Limited | -35.16 Million USD | 92.656% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -7462.518% |
| Genus plc | 178.7 Million USD | 101.445% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 729.649% |
| Marizyme, Inc. | 457.7 Thousand USD | 664.254% |
| ContraFect Corporation | -154 Thousand USD | -1577.013% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -23378.182% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -5065.2% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 3464.469% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 4029.223% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -566.476% |
| MultiCell Technologies, Inc. | 49.32 USD | 5236515.247% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 106.414% |
| EV Biologics, Inc. | 48.9 Thousand USD | 5381.391% |
| Q BioMed Inc. | -8988.00 USD | -28633.867% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 109.14% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -16644.035% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 101.173% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 3789.429% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -1978.535% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 4250.355% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -52052.666% |
| Arch Therapeutics, Inc. | -2439.00 USD | -105787.659% |
| IMV Inc. | -962.29 Thousand USD | -168.378% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 1938.149% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -2548.413% |
| GB Sciences, Inc. | -624.00 USD | -413778.205% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -2902.046% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.034% |
| Halberd Corporation | -208.00 USD | -1241534.615% |
| Enzolytics Inc. | 30.7 Thousand USD | 8510.186% |
| Resverlogix Corp. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 290.297% |
| SYBLEU INC | 11.69 Thousand USD | 22181.053% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 635.328% |
| argenx SE | 1.1 Billion USD | 100.233% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 89.989% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 518.313% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.631% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -29062.15% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 105.822% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | -126.232% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 361.402% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 126.871% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -2980.061% |
| BioStem Technologies, Inc. | 15.42 Million USD | 116.743% |
| ONE Bio Corp. | 20.12 Million USD | 112.833% |
| Reve Technologies, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Agentix Corp. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -21721.715% |
| Cell Source, Inc. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -5251.541% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 1562.732% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 1562.732% |
| NovAccess Global Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -401.953% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | -309.847% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -8805.517% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Qrons Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 673.856% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -708.308% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 156.046% |
| Bioxytran, Inc. | -8285.00 USD | -31071.998% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -592.386% |
| Neutra Corp. | 14.33 Thousand USD | 18116.045% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -3049.512% |
| PureTech Health plc | -1.6 Million USD | -61.11% |
| Coeptis Therapeutics, Inc. | -1 Million USD | -157.941% |
| IXICO plc | 3.27 Million USD | 178.979% |
| IntelGenx Technologies Corp. | -694 Thousand USD | -272.133% |
| Gelesis Holdings, Inc. | -1.79 Million USD | -44.199% |
| CSL Limited | 7.7 Billion USD | 100.034% |
| Cellectis S.A. | 18 Thousand USD | 14447.778% |